Goldman Sachs Maintains Buy on IDEXX Laboratories, Raises Price Target to $650
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Nathan Rich has reaffirmed a Buy rating on IDEXX Laboratories (NASDAQ:IDXX) and increased the price target from $500 to $650.
January 17, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs analyst Nathan Rich maintains a Buy rating on IDEXX Laboratories and raises the price target to $650.
The increase in price target by a reputable analyst like Nathan Rich from Goldman Sachs is a strong positive signal for investors, suggesting a bullish outlook on the stock. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100